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We assessed the eﬃcacy of combined temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma
in a phase II single-institution trial. Twenty-four patients were enrolled. Temozolomide (150mg/m2/day for 7 days every other
week) was administered with concomitant thalidomide (200mg/day), and continued until unacceptable toxicity or disease
progression. There were no complete responses and two (10%) partial responses. Five patients (24%) had stable disease for
at least six months. Fourteen patients (67%) progressed after a median of two-month treatment. The median overall survival
(twenty-two assessable patients) was 9.5 months [95% CI 7–28 months]. There were no treatment-related deaths or CTC grade
4 toxicities. Thirteen patients were dose-reduced or discontinued thalidomide due to toxicity. In conclusion, this combination
of temozolomide and thalidomide provided disease stabilization in a subset of patients with advanced leiomyosarcoma. We
hypothesize that temozolomide is the active agent in this regimen, and should be further studied.
Copyright © 2008 Michelle S. Boyar et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Soft tissue sarcomas are rare tumors, representing less than
1% of all new cancers diagnosed in the United States each
year [1]. Complete surgical resection oﬀers the best chance
of cure for localized soft tissue sarcoma. Patients with
unresectable or metastatic disease have a median survival
of approximately 12 months. Chemotherapy is the main
treatmentoptionforthesepatients.Doxorubicin,ifosfamide,
and dacarbazine (DTIC) each have single-agent activity with
response rates approaching 20% [2–4]. When DTIC was
added to doxorubicin, the response rate and overall survival
increased at the cost of increased toxicity [5].
The use of immunohistochemistry and genetic markers
tobetterdeﬁnesubsetsofsofttissuesarcomasischangingthe
approach to clinical trial design in soft tissue sarcoma. There
isincreasingevidencethatthediﬀerentsubtypesofsofttissue
sarcoma have distinct biologic characteristics which deﬁne
metastaticpotentialandresponsetotherapy.Theremarkable
activity of imatinib in patients with gastrointestinal stromal
tumors is proof of this principle [6]. Instead of large clinical
trials which include a variety of histologic subtypes, newer
trials are limiting enrollment to speciﬁc subtypes to assess
response rates in a subset of patients. This has led to the
identiﬁcation of active regimens for certain subtypes of soft
tissuesarcoma.However,newtherapiesareclearlyneededfor
patients with advanced or metastatic leiomyosarcoma.
Over 50 subtypes of soft tissue tumors have been
described in adults, and leiomyosarcomas are one of the
most common malignant soft tissue sarcomas in adults.
Leiomyosarcomas are derived from smooth muscle cells and
canariseinanylocation.However,morethanhalfarelocated
in retroperitoneal or intraabdominal sites [7].
Temozolomide is a cytotoxic alkylating agent that was
developed as an oral and less toxic alternative to DTIC.
Both temozolomide and DTIC exert their antitumor eﬀects
through the formation of 5-3-methyl-1-triazenolimidazole-
4 carboxamide (MTIC), the putative active chemical2 Sarcoma
metabolite of DTIC [8, 9]. Temozolomide has activity
against malignant gliomas and metastatic melanoma [10,
11]. Based on its similar mechanism of action to dacar-
bazine, temozolomide has been evaluated in soft tissue
sarcoma using a variety of dosing schedules. In several
studies which included a variety of STS subtypes, all of the
clinical beneﬁt was seen in patients with leiomyosarcoma
[12–14].
Thalidomide is an agent shown to be useful in a variety
of tumors. Its mechanisms of action in cancer may be
multiple, including direct cytotoxic, antiangiogenic, and
anti-inﬂammatory eﬀects [15]. The combination of temo-
zolomide and thalidomide has shown promising activity in
metastatic melanoma [16] and metastatic neuroendocrine
tumors [17], where it led to increased response rates
when compared to temozolomide as a single agent. We
conducted this single-institution phase II trial to assess
the eﬃcacy of a combination regimen of temozolomide
and thalidomide in patients with unresectable or metastatic
leiomyosarcoma.
2. PATIENTS AND METHODS
2.1. Studypopulation
The study population consisted of adult patients (age ≥18)
with histologically conﬁrmed, locally advanced, unresectable
or metastatic leiomyosarcoma. Prior treatment with up to
three prior systemic chemotherapy regimens for advanced
disease was permitted, as was previous dacarbazine treat-
ment. Prior radiation therapy was allowed if completed
at least 4 weeks prior to study drug administration.
Patients were required to have at least one unidimensional
measurable lesion documented on computed tomography
(CT). Previously radiated lesions were excluded unless there
was evidence of disease progression at that site prior to
enrollment. Further inclusion criteria included: SWOG per-
formance status of 0–2, life expectancy >2 months, adequate
bone marrow function (absolute neutrophil count [ANC]
≥1500/μL, platelets >70000/μL, and hemoglobin ≥10g/dL),
adequate hepatic function (bilirubin < upper limit of normal
[ULN], AST or ALT <1.5 X ULN, alkaline phosphatase <2
XU L No r≤5 X ULN with documented liver metastases),
and adequate renal function (creatinine <1.5 X ULN, BUN
<1.5 X ULN). Exclusion criteria included brain metastases,
more than 3 prior chemotherapy regimens for treatment
of leiomyosarcoma, insuﬃcient recovery from toxicities of
prior therapies, other serious medical or psychiatric illness,
inability to take oral medications, prior malignancy other
than curatively treated carcinoma in situ of the cervix
or skin cancer, and pregnant or nursing women. Prior
chemotherapy, radiation therapy or surgery must have been
completed at least four weeks prior to enrollment. All
patients and physicians participated in the Enhanced STEPS
program (Enhanced System for Thalidomide Education
and Prescribing Safety). All patients gave written informed
consent before study entry. The study was approved by
the local institutional review board committee and was
conducted in accordance with the ethical principles stated
in the Declaration of Helsinki and the guidelines on good
clinical practice.
2.2. Studydesign
Patients received treatment with temozolomide at a dose of
150mg/m2/day orally on days 1 to 7 and days 15 to 21.
Thalidomide was administered daily at a dose of 200mg. No
dose escalations were permitted. Cycles were repeated every
28 days. Temozolomide was held if ANC remained <1500/μL
or platelet count <100000/μL, and was not resumed until
hematologicrecovery.Whentreatmentresumed,dosereduc-
tions for temozolomide were made based on nadir platelet
count or ANC. For nonhematologic toxicities of grade 3 or
higher as deﬁned by the National Cancer Institute (NCI)
Common Toxicity Criteria (CTC) grading system, dosage
for the subsequent cycle of temozolomide was reduced to
125mg/m2 for grade 3 toxicity and to 100mg/m2 for grade
4 toxicity. No dose adjustments were required if the toxicity
was judged to be non-drug-related. Treatment was discon-
tinued if the patient was unable to resume therapy within
three weeks or if they experienced unacceptable toxicity
levels. Dose modiﬁcations for thalidomide were made based
on thalidomide-related toxicity. When thalidomide-related
toxicity was noted, the dose of thalidomide was reduced to
100mg daily; patients who experienced toxicity at a dose of
100mg were taken oﬀ thalidomide.
Radiologic assessments of all sites of measurable disease
with CT scan were performed on enrollment and every 8
weeks after starting treatment. Therapy was continued until
evidence of disease progression on CT scan, unacceptable
drug toxicity, delay of both drugs for >21 days, or patient-
initiated withdrawal for any reason. Standard World Health
Organization (WHO) response criteria were used. A com-
plete response (CR) required complete disappearance of
all clinically detectable malignant disease for at least four
weeks. A partial response (PR) required ≥50% decrease
in the sum of the products of the largest perpendicular
diameters of a measurable lesion. Not all lesions had to
show regression to qualify for partial response, but no lesion
should have increased by ≥25%, and no new lesions should
have appeared. Stable disease (SD) was deﬁned as <50%
decrease or <25% increase in the sum of the products
of the largest perpendicular diameters of all measurable
lesions. Progression of disease (PD) was deﬁned as a ≥25%
increase in the sum of products of measurable lesions, clear
worseningofanyevaluabledisease,orappearanceofanynew
lesions.
2.3. Statisticalanalysis
This was an open-label, phase II study conducted at
Columbia University Medical Center. The primary end point
in this trial is response (complete and partial response)
rate. A response probability of 25% would be of interest,
while further testing would not be pursued if the response
probability was 5% or lower. Initially, 15 patients would
be entered. If at least one response was observed, an
additional 10 patients will be entered into the trial. FourMichelle S. Boyar et al. 3
or more responses out of a total of 25 patients would
be considered as evidence warranting further study of
this regimen, provided that other factors, such as toxicity
and survival were favorable. This design has a signiﬁcance
level (probability of falsely declaring an agent with a 5%
response probability to warrant further study) of 5%, and
a power (probability of correctly declaring an agent with
a 25% response probability to warrant further study) of
90%.
Time to progression, overall survival, safety, and toxicity
were assessed as secondary outcomes. Time to progression
(date of initiation of treatment to date of progression or
death) and overall survival (time from treatment initiation
to the date of death) were assessed with Kaplan-Meier
estimator. Toxicity and complications of treatment were
assessed based on patient reports of adverse events, physical
examination, and laboratory measurements.
3. RESULTS AND DISCUSSION
3.1. Patientcharacteristics
A total of 25 patients were entered on the study from
February 2002 to November 2004. One patient was found
to be ineligible and withdrawn from the study before receiv-
ing therapy; that patient was excluded from the analysis.
Demographics and baseline disease characteristics for the
24 treated patients are presented in Table 1. Patients had
a median age of 60 years (range from 27 to 75 years);
22 (92%) were females and 2 (8%) males. Median SWOG
performance status was 1. All patients had biopsy-proven
leiomyosarcoma. The primary site was uterus in 11 (46%)
of patients. Other primary sites included retroperitoneum
(n = 3, 13%), small or large intestine (n = 3, 13%),
ovarian (n = 1, 4%), and unknown (n = 3, 13%). All
patients had evidence of metastatic disease. Fifteen patients
(63%) had lung metastases and fourteen patients (58%)
had liver metastases. Eight patients (33%) had metastases
to bone or soft tissue. Twenty patients (83%) had received
prior chemotherapy, including treatment with doxorubicin
(n = 16, 67%) and/or dacarbazine (n = 4, 17%) and others.
The median number of prior regimens was 2. Fourteen
patients (58%) had prior surgery, and three (13%) had prior
radiation therapy.
3.2. Durationoftreatment
Ofthe25patientsconsentedforthetrial,24patientsreceived
treatment for a median of two months (range from 0.5 to
25 months) (Table 2). Five patients received treatment for 6
months or more. Three patients received treatment for less
than 1 cycle due to rapidly progressive disease (n = 2), and
withdrawal of consent (n = 1). Two patients required dose
reduction of temozolomide due to neutropenia and throm-
bocytopenia. Thirteen patients required dose reduction of
thalidomide (n = 8) or discontinued thalidomide (n = 5)
d u et on e u r o p a t h yo rf a t i g u e .
Table 1: Baseline patient characteristics.
Characteristics Patients (N = 24) Percent
No. (%)
Age, years
Median 60
Range 27–75
Sex
Male 2 8
Female 22 92
SWOG performance status
01 4
11 8 7 5
25 2 0
Histology
Leiomyosarcoma 24 100
Primary site
Uterus 11 46
Retroperitoneum 3 13
Other 10 42
Sites of metastases
Lung 15 63
Liver 14 58
Other 8 33
Prior treatment
Surgery 14 58
Radiotherapy 3 13
Chemotherapy 20 83
Doxorubicin 15 67
Dacarbazine 4 17
No. of prior chemo regimens
04 1 7
16 2 5
29 3 8
35 2 1
3.3. Toxicity
Twenty one patients were assessable for toxicity, which is
summarized in Table 3. Grade 2 or 3 neutropenia developed
in three patients (12%), and grade 2 or 3 thrombocytopenia
developed in 4 patients (17%). Dose reduction of temo-
zolomide was required in 3 patients. Grade 2 or 3 anemia
was seen in 3 patients. There were no grade 4 hematologic
toxicities.
Fatigue was the most common nonhematologic toxicity
with grade 2 or 3 fatigue occurring in 13 (54%) patients,
and attributed primarily to thalidomide toxicity. Grade 2
or 3 nausea and emesis occurred in 8 (33%) and 10 (41%)
of patients. Neurologic toxicity occurred in 8 patients and
was primarily neuropathy, however, one patient had grade
3 vision loss, and two patients had grade 3 ataxia. Other
toxicities were relatively mild and consisted of grade 2
anorexia in ﬁve patients (21%), grade 2 constipation in 104 Sarcoma
Table 2: Response, location of primary disease, prior therapy, and duration of therapy (days).
Enrolled patient ID No. Response Primary site of disease Prior chemotherapy regimens Duration of therapy (days)
1 PD Colon and duodenum Dox 34
2 PD Uterus Dox/taxotere; Ifos/DTIC/etoposide; gleevec 16
3 PD Uterus Dox/ifex; gem/taxotere 37
4 PD Stomach Gleevec; ifex/dox 8
5 PD Retroperitoneal Doxil; ifos; taxotere/gem; digitoxin 25
6 SD Unknown Dox/ifex ∗114/398
7 PD Iliopsoas Dox; gem/taxotere 42
8 PR Retroperitoneal None ∗382/389
9 PD Ovarian Doxo/ifex; gem/taxotere 45
10 PD Uterus Doxil, gem 62
11 PD Uterus Gem/taxotere 56
12 PD Pelvic mass Gem/taxotere ∗36/62
13 PR Uterus Dox/ifos; gem/taxotere 670
14 PD Unknown DTIC/doxo; gem/taxotere; digitoxin; ifos 50
15 SD Uterus Dox/ifox/taxotere 186
16 PD Uterus Gem/taxotere 52
17 SD Uterus Dox; gem; taxotere 143
18 SD Uterus None ∗157/207
19 PD Colon None 37
20 PD Uterus Ifos; gem ∗30/53
21 PD Kidney None 78
22 PD Small bowel Dox/avastin; gem; DTIC 53
23 SD Retroperitoneal MAID; vin/doxo/cytoxan 383
24 PD Uterus Gem/taxotere 36
∗ For the 5 patients who discontinued thalidomide early, the fraction represents duration of therapy in days for Temodar + Thalidomide over total days of
therapy with Temodar.
patients (42%), and grade 2 edema in three patients (13%).
There were no infectious complications due to treatment.
3.4. Efﬁcacy
Twenty one patients completed at least one cycle and were
assessable for treatment response. There were no com-
plete responses. Two patients experienced durable partial
responses. The overall radiologic response rate was 10%.
Five (24%) patients experienced stable disease, and 14 (67%)
had disease progression. The two patients with radiographic
responses had durable responses lasting 24 and 25 months
before disease progression. For the ﬁve patients who had
disease stabilization, the median duration of stable disease
was 15 months (range from 6 to 24 months). The median
follow-up time for the patient cohort is 41 months (range
from 18 to 51 months). Twenty three patients developed
progressive disease while receiving therapy, and the median
progression-free survival was 2 months with 95% CI (2
months–6 months) as shown in Figure 1.T w e n t yt w o
patients are assessable for survival and the median overall
survival for the cohort is 9.5 months with 95% CI (7
months–28 months). The one-year survival rate was 40.9%
with 95% CI (24.8%, 67.6%), and the 2-year survival rate
was 26.5% with 95% CI (13.1%, 53.9%) (Figure 2).
Table 3: Most common or serious hematologic and nonhemato-
logic toxicities.
Toxicity Grade 2 Grade 3 Grade 4
No. % No. % No. %
Hematologic
N e u t r o p e n i a 2814
T h r o m b o c y t o p e n i a 31 31 4
A n e m i a 2814
Non-hematologic
Nausea 8 33
Emesis 8 33 2 8
Fatigue 12 50 1 4
Neurologic toxicity 5 21 3 12
Constipation 10 42
Anorexia 5 21
Edema 3 13
The results of this study suggest that the combination of
temozolomide given on an alternating weekly schedule with
daily thalidomide has minimal clinical activity in patients
with locally advanced or metastatic leiomyosarcoma. Two
(10%) out of 21 patients evaluable for response had a
partial response by WHO response criteria. Five patientsMichelle S. Boyar et al. 5
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Figure 1: Time for disease progression.
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Figure 2: Overall survival.
(24%) had disease stabilization for at least 6 months while
receiving treatment. The overall response rate in this study
is lower than what has been reported with DTIC alone [4].
Despite the low response rate, both patients on this trial
with radiographic responses had durable responses lasting
24 and 25 months before disease progression. The median
survival of 9.5 months is typical for this advanced stage,
heavily pretreated patient population.
Temozolomide has been evaluated in soft tissue sarcoma
using several diﬀerent dosing schedules. In our institution,
a phase II trial enrolled 26 patients with unresectable or
metastatic soft tissue sarcoma who were treated with temo-
zolomide administered twice daily on a 12-hour schedule
for 5 days as an oral bolus dose of 200 mg/m2 followed
by 9 doses of 90 mg/m2 every four weeks. There were 2
partial responses, 2 mixed responses, and 3 patients with
stable disease lasting >6 months, for an overall objective
response rate of 8%. All of the patients with clinical beneﬁts
had leiomyosarcoma, none of the other soft tissue sarcoma
histologic subtypes had any beneﬁt [12]. Another phase II
study was conducted in 60 soft tissue sarcoma patients (19
with GIST and 41 with other STS histologies). There were
no responses seen in the patients with GIST, and 22% had
stable disease. Of the evaluable patients with other soft tissue
sarcomas, there was 1 CR and 1 PR for a total response rate
of 5%, another 33% had stable disease. The median time to
progressionandmedianoverallsurvivaltimeinpatientswith
other STS was 3.3 months and 11 months [13]. A phase II
study by the EORTC treated 31 patients with advanced STS
with temozolomide dosed at 750mg/m2 over 5 days during
cycle1andthen1000mg/m2 over5daysatcycle2.Therewas
only 1 partial response for an overall response rate of 3.33%.
The median TTP was 2 months and the median OS was 6.75
months [14].
The Spanish Group for Research on Sarcomas conducted
a phase II trial of temozolomide given as daily for 6
weeks at a dose of 75mg/m2/day–100mg/m2/day. They
enrolled 49 patients with pretreated STS and 18 patients
with GIST. Among the patients in the STS arm, there were
7 PR for an overall response rate of 15.5%. There were
11 patients with gynecologic leiomyosarcoma enrolled, 5 of
which showed response. The median response duration was
12.5 months (range from 3.9 to 58 months). In 4 patients
the response lasted over one year. The median TTP was 2.2
months and median OS was 8.1 months. The drug was well
tolerated at this dose and grade 3-4 hematologic toxicities
were seen in 10–15% of patients. This suggested that the
extended daily dosing schedule had activity in patients
with gynecologic leiomyosarcoma [18]. Memorial Sloan-
Kettering published their experience with temozolomide in
patients with pretreated leiomyosarcoma from 2001 to 2004.
Twelve patients were treated with continuous daily dose
temozolomide, there was one PR which lasted 4 cycles and 4
patients had stabilization of disease from 2 to 5 cycles. Seven
patients were treated with bolus dose temozolomide. One
patienthadanearCRwhichlasted13cyclesandfourpatients
had disease stabilization lasting from 3 to 16 cycles [19]. The
collective evidence from these phase II trials suggested that
leiomyosarcomas, particularly uterine leiomyosarcomas may
be more responsive to treatment with temozolomide than
other STS histologic subtypes.
In our study, enrollment was limited to patients with
leiomyosarcoma, but patients with leiomyosarcoma orig-
inating from any site were eligible. Although there were
only two partial radiographic responses among the evaluable
patients (10%), the duration of response for both patients
was prolonged, lasting 24 and 25 months, respectively. Other
groups have also reported patients with durable responses
lasting over 12 months [18]. The signiﬁcance of this ﬁnding
in a disease where the median progression-free survival
ranges from two to three months suggests there is a cohort of
leiomyosarcoma patients who may derive signiﬁcant beneﬁt
from treatment with temozolomide.
The relative contribution of thalidomide to the anti-
tumor eﬃcacy in this study is diﬃcult to determine.
Although the reported toxicities were generally mild, grade
2 thalidomide-related toxicities such as fatigue, constipation,
and neurologic toxicity were seen in up to 50% of patients.
Dose reduction or discontinuation of thalidomide was
required in 13 (54%) of patients. Patients who contin-
ued treatment with temozolomide had continued beneﬁt
even after stopping the thalidomide. We concluded that6 Sarcoma
thalidomide was poorly tolerated, and it is unlikely to add
additional antitumor eﬃcacy in this patient population. Our
results and those of other groups suggest that temozolomide
is the active agent in this regimen.
4. CONCLUSIONS
In conclusion, temozolomide oﬀers another option to con-
siderinthetreatmentofpatientswithadvancedormetastatic
leiomyosarcoma. Its beneﬁts include the convenience of oral
administrationandanimprovedside-eﬀectproﬁlecompared
to traditional chemotherapy regimens for advanced soft
tissue sarcoma. Although it does not produce high response
rates, there are a number of patients who have disease sta-
bilization from months to years even without radiographic
responses. There are very few chemotherapy regimens that
oﬀer the possibility of beneﬁt in this patient population,
and our data support the consideration of temozolomide
in the treatment of progressive disease. Although several
dosing schedules have been tested in trials (continuous daily
dosing, bolus dosing and biweekly dosing), there is not
suﬃcient evidence to support adopting an alternative dosing
schedule, therefore, we recommend using the 5-day bolus
dosing regimen for temozolomide.
Future investigation should focus on determining the
biologic and molecular characteristics of leiomyosarco-
mas that can predict response to temozolomide. Methyla-
tion of the DNA repair protein 06-methylguanine-DNA-
methyltransferase (MGMT) has been identiﬁed as a pre-
dictor of response to temozolomide treatment in patients
with glioblastoma multiforme [20]. Epigenetic silencing of
MGMT and/or other key regulatory genes in tumor cells
may play a role in temozolomide resistance, and in the
pathogenesis of soft tissue sarcomas. Because of the potential
therapeutic beneﬁts to those patients who may respond
to temozolomide, investigation of mechanisms of response
and resistance to this drug warrants further investigation in
leiomyosarcomas.
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